THE EXECUTIVE BUYING BLOG

Mid-July 2026 Edition This market has been very choppy since mid-May. It looks like it will break out of this consolidation area one way or another very soon. Here are the list of companies on our newsletter. AMGN (Amgen Inc.) Amgen has shown steady progress in the biotech space with strong demand for established therapies and advancement in its obesity pipeline. Recent financials highlight growth from key products, while the company raised full-year guidance following a soli

Please review the following additions to the newsletter: AMGN (Amgen Inc.) Amgen continues to demonstrate resilience in the biotech sector with solid financial performance. In Q1 2026, the company reported strong revenue growth driven by key products like Repatha, Evenity, and Tezspire, while advancing its obesity pipeline candidate MariTide through Phase III trials with promising monthly dosing potential. Shares have shown steady gains amid broader healthcare momentum, suppo

Adding Positions in Tech, Growth, and Healthcare We are adding the following positions to our semi-monthly model newsletter portfolio. Each offers compelling risk/reward in the current environment of AI leadership, small-cap rotation, and innovation-driven growth. Below is a concise breakdown for each. ORCL (Oracle) Oracle remains a top AI infrastructure play with accelerating cloud revenue and massive backlog growth from hyperscaler partnerships. The company continues to ben

On April 11th, a bonus edition of the Executive Buying Newsletter highlighted a significant insider purchase of shares in OSCR at $11.09 per share. By the following Monday morning, investors could have bought OSCR shares at $14.05. Less than a month later, the stock is trading at $21.31, marking an increase of over 51%. This remarkable jump offers valuable lessons on how to spot profitable opportunities by following insider activity and understanding market trends. This post